This early-phase study tests a new type of immunotherapy called BAFFR-targeting CAR T cells for adults whose B-cell acute lymphoblastic leukemia has come back or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, modified to recognize…
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC